Talk:Neuvenge

Medicine: Hematology-oncology Low‑importance

	Medicine portal This article is within the scope of WikiProject Medicine, which recommends that medicine-related articles follow the Manual of Style for medicine-related articles and that biomedical information in any article use high-quality medical sources. Please visit the project page for details or ask questions at Wikipedia talk:WikiProject Medicine.MedicineWikipedia:WikiProject MedicineTemplate:WikiProject Medicinemedicine articles
Low	This article has been rated as Low-importance on the project's importance scale.
	This article is supported by the Hematology-oncology task force.

"History" Section Needs Revision[edit]

The History section is not fully relevant to Neuvenge. I believe it would fit better on Wikipedia's page on cancer vaccines. Additionally, it is poorly written. I would revise, but since it probably doesn't belong on this page anyway, I used my time to write this note. --Cheddar3210 (talk) 05:41, 25 July 2013 (UTC)[reply]

This[edit]

This is a DNDN secondary product still in clinical trials. Bgordski (talk) 20:59, 15 December 2010 (UTC)[reply]

How Neuvenge works (con't)[edit]

Upgrading the immune system’s T-cells with special proteins, a process called Active Cellular Immunotherapy (ACI), lets them hunt down cancer cells via the antigens embedded on their surface. — Preceding unsigned comment added by Bgordski (talk • contribs) 18:49, 20 December 2010 (UTC)[reply]